Literature DB >> 26857709

Accentuated hyperparathyroidism in type II Bartter syndrome.

Daniel Landau1,2, Evgenia Gurevich3,4, Levana Sinai-Treiman5, Hannah Shalev3,4.   

Abstract

BACKGROUND: Bartter syndrome (BS) may be associated with different degrees of hypercalciuria, but marked parathyroid hormone (PTH) abnormalities have not been described.
METHODS: We compared clinical and laboratory data of patients with either ROMK-deficient type II BS (n = 14) or Barttin-deficient type IV BS (n = 20).
RESULTS: Only BS-IV patients remained mildly hypokalemic in spite of a higher need for potassium supplementation. Estimated glomerular filtration rate (eGFR) was mildly decreased in only four BS-IV patients. Average PTH values were significantly higher in BS-II (160.6 ± 85.8 vs. 92.5 ± 48 pg/ml in BS-IV, p = 0.006). In both groups, there was a positive correlation between age and log(PTH). Levels of 25(OH) vitamin D were not different. Total serum calcium was lower (within normal limits) and age-related serum phosphate (Pi)-SDS was increased in BS-II (1.19 ± 0.71 vs. 0.01 ± 1.04 in BS-IV, p < 0.001). The GFR threshold for Pi reabsorption was higher in BS-II (5.63 ± 1.25 vs. 4.36 ± 0.98, p = 0.002). Spot urine calcium/creatinine ratio and nephrocalcinosis rate (100 vs. 16 %) were higher in the BS-II group.
CONCLUSIONS: PTH, serum Pi levels, and urinary threshold for Pi reabsorption are significantly elevated in type II vs. type IV BS, suggesting a PTH resistance state. This may be a response to more severe long-standing hypercalciuria, leading to a higher rate of nephrocalcinosis in BS-II.

Entities:  

Keywords:  Bartter syndrome; Barttin; Hypercalciuria; Nephrocalcinosis; Parathyroid hormone; ROMK

Mesh:

Substances:

Year:  2016        PMID: 26857709     DOI: 10.1007/s00467-016-3337-1

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  25 in total

Review 1.  Understanding Bartter syndrome and Gitelman syndrome.

Authors:  Oliver T Fremont; James C M Chan
Journal:  World J Pediatr       Date:  2012-01-27       Impact factor: 2.764

2.  Hyperparathyroidism in patients with primary aldosteronism: cross-sectional and interventional data from the GECOH study.

Authors:  Stefan Pilz; Katharina Kienreich; Christiane Drechsler; Eberhard Ritz; Astrid Fahrleitner-Pammer; Martin Gaksch; Andreas Meinitzer; Winfried März; Thomas R Pieber; Andreas Tomaschitz
Journal:  J Clin Endocrinol Metab       Date:  2011-10-19       Impact factor: 5.958

3.  Genetic heterogeneity of Bartter's syndrome revealed by mutations in the K+ channel, ROMK.

Authors:  D B Simon; F E Karet; J Rodriguez-Soriano; J H Hamdan; A DiPietro; H Trachtman; S A Sanjad; R P Lifton
Journal:  Nat Genet       Date:  1996-10       Impact factor: 38.330

4.  Correction of hypokalemia with antialdosterone therapy in Gitelman's syndrome.

Authors:  G Colussi; G Rombolà; M E De Ferrari; M Macaluso; L Minetti
Journal:  Am J Nephrol       Date:  1994       Impact factor: 3.754

5.  Recurrent PRKAR1A mutation in acrodysostosis with hormone resistance.

Authors:  Agnès Linglart; Christine Menguy; Alain Couvineau; Colette Auzan; Yasemin Gunes; Mathilde Cancel; Emmanuelle Motte; Graziella Pinto; Philippe Chanson; Pierre Bougnères; Eric Clauser; Caroline Silve
Journal:  N Engl J Med       Date:  2011-06-09       Impact factor: 91.245

6.  A novel compound heterozygous ROMK mutation presenting as late onset Bartter syndrome associated with nephrocalcinosis and elevated 1,25(OH)(2) vitamin D levels.

Authors:  Amita Sharma; Micheal A Linshaw
Journal:  Clin Exp Nephrol       Date:  2011-03-25       Impact factor: 2.801

Review 7.  An improved terminology and classification of Bartter-like syndromes.

Authors:  Hannsjörg W Seyberth
Journal:  Nat Clin Pract Nephrol       Date:  2008-08-12

8.  Evidence for increased renal tubule and parathyroid gland sensitivity to serum calcium in human idiopathic hypercalciuria.

Authors:  Elaine M Worcester; Kristin J Bergsland; Daniel L Gillen; Fredric L Coe
Journal:  Am J Physiol Renal Physiol       Date:  2013-07-17

9.  CLDN16 genotype predicts renal decline in familial hypomagnesemia with hypercalciuria and nephrocalcinosis.

Authors:  Martin Konrad; Jianghui Hou; Stefanie Weber; Jörg Dötsch; Jameela A Kari; Tomas Seeman; Eberhard Kuwertz-Bröking; Amira Peco-Antic; Velibor Tasic; Katalin Dittrich; Hammad O Alshaya; Rodo O von Vigier; Sabina Gallati; Daniel A Goodenough; André Schaller
Journal:  J Am Soc Nephrol       Date:  2007-11-14       Impact factor: 10.121

10.  The neonatal variant of Bartter syndrome and deafness: preservation of renal function.

Authors:  Hanna Shalev; Melly Ohali; Leonid Kachko; Daniel Landau
Journal:  Pediatrics       Date:  2003-09       Impact factor: 7.124

View more
  1 in total

1.  Isolated nephrocalcinosis due to compound heterozygous mutations in renal outer medullary potassium channel.

Authors:  Priyanka Khandelwal; Jasintha Sabanadesan; Aditi Sinha; Pankaj Hari; Arvind Bagga
Journal:  CEN Case Rep       Date:  2020-03-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.